GlassScriptPhysician profile
David L Crooks
NPI 1376615492
$4,211.92
in general payments reported to CMS, 2019-2025
19 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,582 · 2022: $101 · 2023: $341 · 2024: $1,051 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278 · Travel and Lodging: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.44 |
| Travel and Lodging | $1,250.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,228.33 | 2019 | |
| Stryker Corporation | $953.06 | 2024-2025 | 1788 |
| Astrazeneca Pharmaceuticals LP | $436.08 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Elucent Medical | $370.97 | 2025 | |
| Merck Sharp & Dohme LLC | $342.50 | 2022-2025 | Keytruda, Lynparza |
| Tela Bio, INC. | $195.90 | 2019-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Tg Therapeutics, INC. | $193.90 | 2023 | |
| Organogenesis INC. | $101.49 | 2019 | |
| Incyte Corporation | $69.62 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Biotech, INC. | $56.97 | 2025 | Carvykti, Talvey |
| Novartis Pharmaceuticals Corporation | $56.53 | 2024-2025 | |
| Ethicon US, LLC | $40.00 | 2019 | |
| Tactile Systems Technology INC | $36.28 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Lilly USA, LLC | $29.59 | 2025 | |
| Pharmacosmos Therapeutics INC. | $23.13 | 2025 | Monoferric |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.43 | 2024 | Ojjaara |
| Abbott Laboratories | $20.13 | 2019 | |
| Stemline Therapeutics INC. | $19.00 | 2025 | Orserdu |
| Beone Medicines USA, INC. | $16.01 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.